Financial reports
10-Q
2023 Q3
Quarterly report
24 Feb 23
NT 10-Q
Notice of late quarterly filing
14 Feb 23
10-Q
2023 Q2
Quarterly report
14 Nov 22
10-Q
2023 Q1
Quarterly report
12 Aug 22
10-K
2022 FY
Annual report
29 Jun 22
10-Q
2022 Q3
Quarterly report
11 Feb 22
10-Q
2021 Q2
Quarterly report
12 Nov 21
10-Q
2021 Q1
Quarterly report
16 Aug 21
Current reports
8-K
Nemaura Medical Announces Receipt of Notice from Nasdaq
9 Mar 23
8-K
Changes in Registrant's Certifying Accountant
1 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
23 Feb 23
8-K/A
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
22 Feb 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
21 Feb 23
8-K
Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
31 Jan 23
8-K
Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet
26 Jan 23
8-K
Regulation FD Disclosure
25 Jan 23
8-K
Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
24 Jan 23
8-K
Nemaura Medical Reports Fiscal Second Quarter 2023 Results and Provides Business Update
14 Nov 22
Registration and prospectus
S-1
IPO registration
13 Mar 23
424B5
Prospectus supplement for primary offering
31 Jan 23
424B5
Prospectus supplement for primary offering
1 Apr 22
S-3
Shelf registration
16 Mar 22
424B5
Prospectus supplement for primary offering
23 Jul 21
424B5
Prospectus supplement for primary offering
28 Jul 20
424B5
Prospectus supplement for primary offering
27 Jul 20
424B5
Prospectus supplement for primary offering
10 Apr 19
S-3
Shelf registration
27 Mar 19
424B5
Prospectus supplement for primary offering
19 Dec 18
Other
EFFECT
Notice of effectiveness
29 Mar 22
CORRESP
Correspondence with SEC
24 Mar 22
UPLOAD
Letter from SEC
23 Mar 22
EFFECT
Notice of effectiveness
9 Apr 19
CORRESP
Correspondence with SEC
4 Apr 19
UPLOAD
Letter from SEC
4 Apr 19
CT ORDER
Confidential treatment order
8 Jun 18
UPLOAD
Letter from SEC
13 Apr 18
CORRESP
Correspondence with SEC
26 Mar 18
CORRESP
Correspondence with SEC
15 Mar 18
Ownership
4
Salim Natha
1 Feb 22
4
Thomas Peter Moore
1 Feb 22
4
Justin James Mclarney
1 Feb 22
4
Timothy Christopher Johnson
1 Feb 22
4
Dewan Fazlul Hoque Chowdhury
1 Feb 22
4
Bashir Timol
1 Feb 22
3
Thomas Peter Moore
10 Nov 21
3
Timothy Christopher Johnson
2 Nov 21
3
Justin James Mclarney
2 Nov 21
4
Bashir Timol
7 Jun 18